Puromycin is an antibiotic that stops cells from making proteins. First reported in 1952, it was isolated from the soil bacterium Streptomyces alboniger. While it’s too toxic to use as a medicine in people, puromycin became one of the most important tools in molecular biology, used in labs worldwide to study how cells build proteins, to select genetically modified cells, and to measure protein production rates.
How Puromycin Stops Protein Synthesis
To understand puromycin, it helps to know a little about how cells make proteins. Ribosomes, the cell’s protein-building machinery, read genetic instructions and assemble amino acids into chains. Each amino acid arrives attached to a small carrier molecule called transfer RNA (tRNA). The ribosome has two key docking sites: the A-site, where new amino acid carriers land, and the P-site, where the growing protein chain sits.
Puromycin is a molecular mimic. Its structure closely resembles the business end of an amino acid carrier, specifically a modified sugar base linked to a tyrosine amino acid. Because the resemblance is so convincing, the ribosome lets puromycin slip into the A-site as if it were a legitimate amino acid delivery. The ribosome then does what it normally does: it transfers the growing protein chain onto puromycin. But here the trick plays out. Unlike a real amino acid carrier, puromycin can’t continue the chain-building process. The incomplete protein, now permanently attached to puromycin, falls off the ribosome. The result is a truncated, nonfunctional protein fragment released prematurely into the cell.
This mechanism works on both bacterial and animal cells, which is precisely why puromycin is too toxic for clinical use as an antibiotic. It doesn’t distinguish between a pathogen’s ribosomes and a patient’s ribosomes, so it would damage human cells just as effectively as bacterial ones.
Why Labs Use It for Cell Selection
Despite being useless as a medicine, puromycin is extremely useful in genetic engineering. When scientists want to insert a new gene into cells, they face a practical problem: only a small fraction of cells actually take up the gene. They need a way to separate the successfully modified cells from all the rest.
The solution is to include a resistance gene alongside the gene of interest. The most common puromycin resistance gene, called pac, produces an enzyme (puromycin N-acetyltransferase) that chemically deactivates puromycin by attaching an acetyl group to it. When researchers add puromycin to the cell culture, only cells carrying the resistance gene survive. Everything else dies. This gives researchers a clean population of modified cells to work with.
The concentrations needed for selection vary depending on the organism and cell type. In yeast, for example, 20 millimolar puromycin completely blocks growth in normal cells, while cells carrying an active drug-export pump may need lower concentrations around 2.5 to 4 millimolar for effective selection. Mammalian cells typically require much lower concentrations, often in the range of 1 to 10 micrograms per milliliter, though the exact dose depends on the specific cell line. Researchers usually run a “kill curve” experiment first, testing a range of concentrations to find the minimum that eliminates all unmodified cells.
Measuring How Fast Cells Make Proteins
One of puromycin’s cleverest applications takes advantage of the very property that makes it toxic. At low concentrations, puromycin gets incorporated into growing proteins without shutting down the overall production process. The truncated, puromycin-tagged protein fragments can then be detected using antibodies that recognize puromycin itself.
This is the basis of the SUnSET technique (Surface Sensing of Translation), developed in 2009. Researchers expose cells to a brief pulse of low-dose puromycin, then use a standard lab method called western blotting to detect how much puromycin-tagged protein the cells produced. More tagged fragments means the cells were making protein faster. The technique replaced older methods that required radioactive isotopes, making it safer and more accessible. The underlying concept actually dates back to 1979, when researchers first used radioactively labeled puromycin to measure protein production rates in animal tissues under different dietary conditions.
Modeling Kidney Disease in Animals
A modified form of the molecule, puromycin aminonucleoside (PAN), serves a completely different purpose in medical research. PAN is toxic specifically to podocytes, the specialized cells in the kidney that form the filtration barrier. When given to rats, PAN causes these cells to flatten, detach from their supporting membrane, and die, producing a condition that closely resembles idiopathic nephrotic syndrome in humans, a kidney disease marked by protein leaking into the urine.
The damage appears to work through the overproduction of reactive oxygen species in podocytes, leading to disorganization of their internal scaffolding and disruption of the slit diaphragm proteins that normally keep the filtration barrier intact. This animal model has been used for decades to test potential treatments. In one line of research, vitamin D was shown to significantly protect against podocyte damage in PAN-treated rats by preserving key structural proteins and blocking harmful signaling pathways.
Handling and Storage
Puromycin is typically sold as puromycin dihydrochloride, a water-soluble powder. Stock solutions can be prepared in PBS (up to about 15 millimolar), DMSO (up to 20 millimolar), or absolute ethanol (up to 1.5 millimolar). The powder is stable at negative 20 degrees Celsius and should be protected from prolonged light exposure. Stock solutions are best prepared fresh before each use, though solutions in DMSO stored at negative 20 degrees Celsius remain stable for reasonable periods. Published data on long-term solution stability is limited, so most manufacturers recommend making fresh aliquots when possible.